• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [6756 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022 Canary Health Service [Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2022 Canary Health Service [Portable neuromodulation stimulation device to improve gait in multiple sclerosis]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia (Addendum to Commission E21-08)]
2022 Malaysian Health Technology Assessment (MaHTAS) Tertiary care virtual online consultation between doctor and patient
2022 Malaysian Health Technology Assessment (MaHTAS) Molecular profiling assays in early breast cancer
2022 Malaysian Health Technology Assessment (MaHTAS) Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022 Malaysian Health Technology Assessment (MaHTAS) Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022 Malaysian Health Technology Assessment (MaHTAS) Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Patients with hip fracture from low-impact trauma: clinical management of anti-osteoporotic pharmacological treatment to prevent new fractures]
2022 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of the pilates method in selected clinical conditions]
2022 Ontario Health Genetic testing for familial hypercholesterolemia
2022 Ontario Health Pre-surgical nasal decolonization of staphylococcus aureus
2022 The Regional Health Technology Assessment Centre (HTA-centrum) Osseointegrated upper limb prostheses with and without neuromuscular control: benefits and risks
2022 The Regional Health Technology Assessment Centre (HTA-centrum) [Benefits and risks of caseload midwifery: continuity of midwifery team during antenatal, intrapartal, and postnatal care]
2022 The Regional Health Technology Assessment Centre (HTA-centrum) Active or semi-active robotic arm-assisted versus manual knee arthroplasty: benefits and risks
2022 The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of surgical procedures to treat apical prolapse - comparison of sacrospinous fixation, laparoscopic sacrocolpopexy/sacrohysteropexy, and the Manchester procedure
2022 National Authority for Assessment and Accreditation in Healthcare (INEAS) [SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2022 Center for Drug Evaluation (CDE) Patient involvement in the health technology assessment process in Taiwan
2022 The Regional Health Technology Assessment Centre (HTA-centrum) Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies
2022 National Institute for Health and Care Excellence (NICE) Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2022 National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy. NICE technology appraisal guidance 758
2022 National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 760
2022 National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 761
2022 National Institute for Health and Care Excellence (NICE) Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal). NICE technology appraisal guidance 762
2022 National Institute for Health and Care Excellence (NICE) Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 763
2022 National Institute for Health and Care Excellence (NICE) Fremanezumab for preventing migraine. NICE technology appraisal guidance 764
2022 National Institute for Health and Care Excellence (NICE) Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022 National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. NICE technology appraisal guidance 766
2022 National Institute for Health and Care Excellence (NICE) Ponesimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 767
2022 National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 768
2022 National Institute for Health and Care Excellence (NICE) Palforzia for treating peanut allergy in children and young people. NICE technology appraisal guidance 769
2022 National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 770
2022 National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 771
2022 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. NICE technology appraisal guidance 772
2022 National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 773
2022 National Institute for Health and Care Excellence (NICE) Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal). NICE technology appraisal guidance 774
2022 National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 775
2022 National Institute for Health and Care Excellence (NICE) Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 776
2022 National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 777
2022 National Institute for Health and Care Excellence (NICE) Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 778
2022 National Institute for Health and Care Excellence (NICE) Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 779
2022 National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 780
2022 National Institute for Health and Care Excellence (NICE) Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 781
2022 National Institute for Health and Care Excellence (NICE) Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal). NICE technology appraisal guidance 782
2022 National Institute for Health and Care Excellence (NICE) Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 783
2022 National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. NICE technology appraisal guidance 784
2022 National Institute for Health and Care Excellence (NICE) Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal). NICE technology appraisal guidance 785
2022 National Institute for Health and Care Excellence (NICE) Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 786
2022 National Institute for Health and Care Excellence (NICE) Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022 National Institute for Health and Care Excellence (NICE) Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. NICE technology appraisal guidance 788
2022 National Institute for Health and Care Excellence (NICE) Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. NICE technology appraisal guidance 789
2022 National Institute for Health and Care Excellence (NICE) TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal). NICE technology appraisal guidance 790
2022 National Institute for Health and Care Excellence (NICE) Romosozumab for treating severe osteoporosis. NICE technology appraisal guidance 791
2022 National Institute for Health and Care Excellence (NICE) Filgotinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 792
2022 National Institute for Health and Care Excellence (NICE) Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). NICE technology appraisal guidance 793
2022 National Institute for Health and Care Excellence (NICE) Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 794
2022 National Institute for Health and Care Excellence (NICE) Ibrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 795
2022 National Institute for Health and Care Excellence (NICE) Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022 National Institute for Health and Care Excellence (NICE) Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 797
2022 National Institute for Health and Care Excellence (NICE) Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NICE technology appraisal guidance 798
2022 National Institute for Health and Care Excellence (NICE) Faricimab for treating diabetic macular oedema. NICE technology appraisal guidance 799
2022 National Institute for Health and Care Excellence (NICE) Faricimab for treating wet age-related macular degeneration. NICE technology appraisal guidance 800
2022 National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2022 National Institute for Health and Care Excellence (NICE) Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NICE technology appraisal guidance 802
2022 National Institute for Health and Care Excellence (NICE) Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2022 National Institute for Health and Care Excellence (NICE) Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804
2022 National Institute for Health and Care Excellence (NICE) Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. NICE technology appraisal guidance 805
2022 National Institute for Health and Care Excellence (NICE) Belimumab for treating lupus nephritis (terminated appraisal). NICE technology appraisal guidance 806
2022 National Institute for Health and Care Excellence (NICE) Roxadustat for treating symptomatic anaemia in chronic kidney disease. NICE technology appraisal guidance 807
2022 National Institute for Health and Care Excellence (NICE) Fenfluramine for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 808
2022 National Institute for Health and Care Excellence (NICE) Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease. NICE technology appraisal guidance 809
2022 National Institute for Health and Care Excellence (NICE) Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. NICE technology appraisal guidance 810
2022 National Institute for Health and Care Excellence (NICE) Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 811
2022 National Institute for Health and Care Excellence (NICE) Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812
2022 National Institute for Health and Care Excellence (NICE) Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022 National Institute for Health and Care Excellence (NICE) Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022 National Institute for Health and Care Excellence (NICE) Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022 National Institute for Health and Care Excellence (NICE) Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022 National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022 National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. NICE technology appraisal guidance 818
2022 National Institute for Health and Care Excellence (NICE) Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2022 National Institute for Health and Care Excellence (NICE) Brolucizumab for treating diabetic macular oedema. NICE technology appraisal guidance 820
2022 National Institute for Health and Care Excellence (NICE) Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821
2022 National Institute for Health and Care Excellence (NICE) Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal). NICE technology appraisal guidance 822
2022 National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 823
2022 National Institute for Health and Care Excellence (NICE) Dexamethasone intravitreal implant for treating diabetic macular oedema. NICE technology appraisal guidance 824
2022 National Institute for Health and Care Excellence (NICE) Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. NICE technology appraisal guidance 825
2022 National Institute for Health and Care Excellence (NICE) Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2022 National Institute for Health and Care Excellence (NICE) Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy. NICE technology appraisal guidance 827
2022 National Institute for Health and Care Excellence (NICE) Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2022 National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2022 National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2022 National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832